Alnylam Pharmaceuticals ((ALNY)) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Alnylam Pharmaceuticals is conducting a clinical study titled ‘A Randomized, Double-blind, Placebo-controlled Single Ascending Dose and Open-label Multi-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-APP in Adult Patients With Early-onset Alzheimer’s Disease (EOAD)’. The study aims to assess the safety and tolerability of ALN-APP, a drug administered via intrathecal injection, in patients with EOAD. This research is significant as it explores potential treatments for a challenging condition.
The intervention being tested is ALN-APP, a drug designed to be administered intrathecally. Its purpose is to evaluate its safety and effectiveness in treating early-onset Alzheimer’s Disease.
The study follows an interventional design with a randomized allocation and a parallel intervention model. It employs triple masking, meaning the participant, care provider, and investigator are blinded. The primary purpose of the study is treatment-focused.
The study began on January 30, 2022, with primary completion and estimated completion dates not yet reached. The latest update was submitted on August 25, 2025, indicating ongoing progress.
This study update could influence Alnylam Pharmaceuticals’ stock performance positively, as advancements in Alzheimer’s treatment are highly anticipated. Investors may view this as a promising development, potentially boosting sentiment. Competitors in the Alzheimer’s treatment space may also be closely monitoring these developments.
The study is currently recruiting, with further details available on the ClinicalTrials portal.